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Introduction {#sec005}
============

Embryonal tumors of the central nervous system (CNS), i.e. medulloblastoma, atypical teratoid rhabdoid tumor, and CNS primitive neuroectodermal tumors (PNET), are the most common malignant primary brain cancers in children and account for approximately 20% of all pediatric brain tumors \[[@pone.0151465.ref001]\]. Histologically they appear as small round blue progenitor cell tumors, but biologically and molecularly they are distinct entities \[[@pone.0151465.ref002], [@pone.0151465.ref003]\]. CNS-PNETs have an annual incidence of 0.62 per 1,000,000 children in the USA \[[@pone.0151465.ref004]\]. They are treated like high-risk medulloblastomas, resulting in a 5-year disease free survival of 15--50%, which is worse than medulloblastomas (5-year disease free survival of \~80%) \[[@pone.0151465.ref005]--[@pone.0151465.ref007]\]. In analogy to other brain tumors, like gliomas, immunotherapy might be key to improve survival in CNS-PNETs. Therefore, it is of importance to understand the immune response against CNS-PNETs. Efficient killing of CNS-PNETs during immunotherapeutic protocols can only be achieved when potential tumor-associated mechanisms to evade recognition or killing by the immune system are overcome. It has been well established that cancers employ multiple mechanisms to evade our immune system, making them less susceptible for immunotherapy \[[@pone.0151465.ref008]\]. Evidence for the existence of immune evasion strategies in brain tumors comes from gliomas and medulloblastomas, showing that subtypes downregulate MHC-I expression pointing to evasion from T cell-mediated anti-tumor immunity \[[@pone.0151465.ref009], [@pone.0151465.ref010]\] or lack CD1d expression to evade NKT cell recognition \[[@pone.0151465.ref011]\]. Moreover, expression of intracellular apoptosis inhibitors (e.g. caspase inhibitors) to escape from death receptor-induced apoptosis and granzyme-mediated killing pathways \[[@pone.0151465.ref008]\] predicts a worse clinical outcome and poor response to cellular immunotherapy \[[@pone.0151465.ref012], [@pone.0151465.ref013]\]. Whether CNS-PNETs can evade the immune response remains to be elucidated. The aim of this study is to survey several cases of pediatric CNS-PNET for tumor-infiltrating lymphocytes and immune evasion molecules, allowing to facilitate prediction of the tumor response to immunotherapy.

Materials and Methods {#sec006}
=====================

Patients {#sec007}
--------

We examined by immunohistochemistry the cytotoxic immune response and immune evasion strategies in seven primary pediatric CNS-PNETs operated between 1998--2014 at the University Medical Center Utrecht (Utrecht, The Netherlands). Patient characteristics are shown in [Table 1](#pone.0151465.t001){ref-type="table"}. The study material was derived from the archive of the Department of Pathology of the University Medical Center Utrecht, Utrecht, The Netherlands and distributed by the Biobank of the Department of Pathology. The biobank is overseen by the institutional medical ethical review board.
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###### Patient characteristics.

![](pone.0151465.t001){#pone.0151465.t001g}

  Case    Gender   Age (years)   Location                       Histology[^†^](#t001fn001){ref-type="table-fn"}   Survival (months)   GFAP[\*](#t001fn002){ref-type="table-fn"}   NeuN[\*](#t001fn002){ref-type="table-fn"}   Synaptophysin\*   Ki-67[\*](#t001fn002){ref-type="table-fn"}   Ini1[\*](#t001fn002){ref-type="table-fn"}   β-catenin
  ------- -------- ------------- ------------------------------ ------------------------------------------------- ------------------- ------------------------------------------- ------------------------------------------- ----------------- -------------------------------------------- ------------------------------------------- -------------
  **1**   Female   2             Frontal lobe bilateral         CNS PNET, NOS                                     Died (21)           0                                           0                                           100               75                                           100                                         Cytoplasmic
  **2**   Female   2             Insula left                    CNS PNET, NOS                                     Died (2)            \<1                                         0                                           90                50                                           100                                         Cytoplasmic
  **3**   Female   2             Frontal-temporal lobe right    CNS PNET, NOS                                     Died (10)           0                                           0                                           \<1               95                                           100                                         Cytoplasmic
  **4**   Male     9             Frontal lobe right             CNS PNET, NOS                                     Died (5)            \<1                                         0                                           90                65                                           100                                         Cytoplasmic
  **5**   Female   17            Frontal lobe/ regio pinealis   CNS PNET, pineoblastoma                           Alive (50)          0                                           0                                           100               10                                           100                                         Cytoplasmic
  **6**   Female   7             Parieto-ocipital lobe right    CNS PNET, Ependymoblastoma                        Died (25)           40                                          5                                           30                5                                            100                                         Cytoplasmic
  **7**   Female   2             Insula left                    CNS PNET, Ependymoblastoma                        Died (4)            75                                          \<1                                         0                 75                                           100                                         Cytoplasmic

^†^Tumors were reclassified according to the 4^th^ edition of the WHO classification of tumors of the central nervous system.

\*Values are displayed as percentage positive tumor cells.

Since we are using archival pathology material which does not interfere with patient care and does not involve physical involvement of the patient, no ethical approval is required according to Dutch legislation \[[@pone.0151465.ref014]\]. Use and storage of anonymous or coded left over material for scientific purposes is part of the standard treatment contract with patients and therefore informed consent procedure was not required according to our institutional medical ethical review board, this has also been described by van Diest \[[@pone.0151465.ref015]\].

Immunohistochemistry {#sec008}
--------------------

Immunohistochemistry was carried out on 4μm thick formalin fixed paraffin embedded consecutive sections. For tumor classification, all stainings (GFAP, Synaptophysin, Neu-N, Ini1, β-catenin, Ki-67) were repeated using an automated immunostainer (Benchmark Ultra, Ventana, Roche). All other stainings were performed manually, except CD4 and SerpinB1 that were stained using the immunostainer. After deparaffination and rehydration, endogenous peroxidase activity was blocked for 15 min in a buffer solution pH5.8 containing 0.3% hydrogen peroxide. After antigen retrieval, i.e. boiling for 20 min in 10 mM citrate pH6.0, or Tris/EDTA pH9.0, a cooling off period of 30 min preceded the primary antibody incubation. All primary antibodies were diluted in PBS containing 2% BSA and incubated for 1h at room temperature (NKp46 and SERPINB4 were incubated o/n at 4°C). Antibody dilutions can be found in [Table 2](#pone.0151465.t002){ref-type="table"}. The signal was amplified using Brightvision poly-HRP anti-mouse, rabbit, rat (DPVO-HRP, Immunologic) or in case of NKp46 with rabbit anti-goat HRP (DAKO), or in case of SERPINB4 the Novolink kit (Leica), and developed with diaminobenzidine followed by counterstaining with haematoxylin, dehydration in alcohol and mounting. The γδ-TCR staining was performed by boiling in 10 mM citrate pH6.0 for 2 min in a pressure cooker, followed by washing with TBS-T for 5 min (DAKO) and blocking with 5% Human serum in PBS for 30 min and avidin-biotin blocking (DAKO) for 20 min prior to antibody incubation. Signal amplification was performed using the REAL Detection System, Alkaline Phosphatase/RED, Rabbit/mouse (DAKO) followed by counterstaining with haematoxylin and mounting. Appropriate positive and negative controls were included in all stainings.
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###### Overview of used antibodies.

![](pone.0151465.t002){#pone.0151465.t002g}

                     Antigen retrieval   clone        Company                           dilution
  ------------------ ------------------- ------------ --------------------------------- -----------
  GFAP               EDTA                27G12        Novocastra                        1:200
  Synaptophysin      EDTA                6F2          Dako                              1:1,000
  Neu-N              EDTA                Mab377       Chemicon                          1:500
  Ini1               EDTA                CL25/Baf47   BD Biosciences                    1:100
  β-catenin          EDTA                17C2         Novocastra                        1:20
  Ki-67              EDTA                M7240        Dako                              1:100
  HLA-A              Citrate             HCA2         Ref. \[[@pone.0151465.ref029]\]   1:100
  HLA-B              EDTA                HC10         Ref. \[[@pone.0151465.ref029]\]   1:200
  CD1d               EDTA                NOR3.2       Thermo Scientific                 1:100
  β2-microglobulin   None                A072         Dako                              1:600
  CD3                EDTA                A452         Dako                              1:100
  CD4                EDTA                SP35         CellMarque                        1:50
  CD8                Citrate             M7103        Dako                              1:50
  CD20               Citrate             M0755        Dako                              1:800
  FOXP3              EDTA                150D/E4      Ebioscience                       1:100
  NKp46              EDTA                AF1850       R&D Systems                       1:200 o/n
  γTCR               Citrate             Gamma3.20    Thermo Scientific                 1:40
  CD34               Citrate             QBEnd10      Immunotech                        1:800
  Bcl-2              Citrate             M0887        Dako                              1:200
  Survivin           Citrate             71G4B7       Cell Signaling                    1:400
  SERPINB1           Citrate             Ab47731      Abcam                             1:800
  SERPINB4           EDTA                10C12        Santa Cruz                        1:50 o/n
  SERPINB9           Citrate             Clone 17     Ref. \[[@pone.0151465.ref030]\]   1:400
  Granzyme B         Citrate             GB7          Ref. \[[@pone.0151465.ref031]\]   1:250

Scoring of immunohistochemistry {#sec009}
-------------------------------

Reclassification of cases was performed independently by two experienced neuropathologists (WGSS and WVH). All scoring was done blinded to patient characteristics and results of other staining by three independent observers (JFV, WGSS, WVH). Analysis of the immune influx was performed on whole slides at 20x magnification. Immune influx was corrected for the size of tissue on the slide and the tumor percentage as calculated with the manufacturers algorithm based on digitalized immunochemical slides using a digital slide scanner (Aperio Technologies Inc.). Serpin expression was scored as present (+) or absent (-), because serpins were uniformly expressed throughout the tumor.

Statistics {#sec010}
----------

Statistical analysis was performed using IBM SPSS version 21 (SPSS Inc.). Descriptive statistics were examined as median and inter quartile range (IQR) taking all patients into account. No statistical tests or survival analyses were performed due to the number of patients included in this study.

Results and Discussion {#sec011}
======================

We found a substantial and highly variable influx of immune cells from the (tumor-associated) vasculature into the tumor tissue, i.e. 28.5 (43.7) \[median (IQR)\] CD3^+^ T-cells and 6.4 (13.3) CD20^+^ B-cells per 2mm^2^ tumor tissue. Normal brain parenchyma did not contain CD3^+^ T-cells or CD20^+^ B-cells. Data on individual patients is shown in [Table 3](#pone.0151465.t003){ref-type="table"}. The CD3/CD20 ratio in the tumor tissue was 7.0 (12.6). The immune cell influx was independent of the vascular density. Leucocytosis or leucocytopenia prior to surgery, as determined by routine laboratory blood tests, was absent in all patients. The CD3^+^ T-cell population consisted of 9.6 (27.8) CD8^+^ T-cells and 8.7 (16.1) CD4^+^ T-cells per 2mm^2^ tumor tissue \[CD8^+^ /CD4^+^ T-cell ratio of 1.2 (0.3)\]. Next, we studied the influx of γδ-T-cells, an additional cytotoxic lymphocyte subset \[[@pone.0151465.ref016], [@pone.0151465.ref017]\]. We detected low numbers of γδ-T-cells in CNS-PNET \[0.1 (0.2)\]. Recruitment of NKp46^+^ NK-cells could not be detected in CNS-PNET, which is in line with results in other CNS tumors \[[@pone.0151465.ref018], [@pone.0151465.ref019]\]. The activity of cytotoxic tumor-infiltrating lymphocytes was examined by granzyme B (GrB) expression, resulting in a GrB-positive CTL fraction of 8.4% (8.4%). One patient (Case 1, [Fig 1](#pone.0151465.g001){ref-type="fig"}) had 29.0% GrB positive CTLs whereas all the other patients had \<10% GrB positive CTLs (Case 2 is shown as an example, [Fig 1](#pone.0151465.g001){ref-type="fig"}).

![Immune (evasion) markers in cases of CNS-PNET.\
Immunohistochemical staining of immune markers in two CNS-PNET cases. Note that SerpinB9 expression coincides with high numbers of activated GrB ^+^ CTLs in case 1 versus low numbers of activated GrB ^+^ CTLs in case 2. Size bar equals 50μm.](pone.0151465.g001){#pone.0151465.g001}
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###### Results on infiltrating immune cells and Granzyme inhibitor expression of the individual patients.

![](pone.0151465.t003){#pone.0151465.t003g}

  Case    CD3^+^   CD4^+^   CD8^+^   CD20^+^   FOXP3^+^   NKp46^+^   γTCR^+^   CD3/CD20 ratio   CD8/CD4 ratio   GrB^+^ CTL fraction   SERPINB1                               SERPINB4                               SERPINB9
  ------- -------- -------- -------- --------- ---------- ---------- --------- ---------------- --------------- --------------------- -------------------------------------- -------------------------------------- --------------------------------------
  **1**   15.92    5.41     6.37     6.39      0.33       0          0.74      2.49             1.18            0.29                  [-](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}
  **2**   11.14    4.55     3.37     1.11      0.32       0          0.31      10.00            0.74            0.066                 [+](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}
  **3**   6.41     2.55     3.59     10.81     0.061      0          0.061     0.59             1.41            0.014                 [-](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}
  **4**   110.03   44.22    51.06    15.78     0.14       0          0.24      6.97             1.15            0.099                 [+](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}
  **5**   54.86    20.63    31.40    3.95      1.30       0          n.a.      13.88            1.52            0.084                 [-](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}
  **6**   38.83    15.27    16.27    2.51      0.23       0          0.028     15.45            1.07            0.015                 [-](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}
  **7**   28.46    8.70     9.57     21.85     0.17       0          0.26      1.30             1.10            0.099                 [-](#t003fn002){ref-type="table-fn"}   [+](#t003fn002){ref-type="table-fn"}   [-](#t003fn002){ref-type="table-fn"}

Values are displayed as number of immune cells per 2mm^2^ tumor tissue.

\+ and - indicates presence or absence of expression of SERPINs, respectively

Given the modest cytotoxic lymphocyte activation, we wondered whether CNS-PNETs downregulate MHC-I (HLA-A and HLA-B) and/or CD1d to avoid CTL, NKT, and/or CD1d-restricted γδ-T-cell \[[@pone.0151465.ref020]\] recognition. Whereas normal brain tissue, blood vessels, and infiltrating immune cells readily express these HLA molecules and CD1d, we found that HLA-A, HLA-B, and CD1d expression was not detectable in all CNS-PNET cases ([Fig 1](#pone.0151465.g001){ref-type="fig"}). In addition, β2-microglobulin expression was decreased concordantly (data not shown). We detected low numbers of FOXP3^+^ regulatory T-cells \[0.2 (0.3) per 2mm^2^ tumor tissue\], which may contribute to attenuation of immune activity. Together, these data suggest that pediatric CNS-PNETs may evade recognition by cytotoxic immune cells.

Granzymes are the major tumor killing molecules secreted by cytotoxic cells. In humans, five granzymes (i.e. GrA, GrB, GrH, GrK, and GrM) exist with distinct substrate specificities and only partially overlapping routes of apoptosis induction \[[@pone.0151465.ref021]\]. Certain tumors can express serine protease inhibitors (serpins) to directly block granzyme activity. It has been well established that SERPINB9 (GrB inhibitor also called PI-9) expression in melanomas correlates with worse clinical outcome and poor response to immunotherapy \[[@pone.0151465.ref013]\]. For brain tumors in general, it remains unknown whether granzyme inhibitors are expressed. Intriguingly, we now show that 29% of CNS-PNETs had expression of the GrB inhibitor SERPINB9 ([Fig 1](#pone.0151465.g001){ref-type="fig"}). We found that SERPINB9 expression was absent in the normal brain parenchyma, indicating that SERPINB9 expression is acquired during tumorigenesis. Remarkably, high SERPINB9 expression was constrained to the case with high cytotoxic lymphocyte activation. We also addressed the expression of the GrH and GrM inhibitors (SERPINB1 \[[@pone.0151465.ref022]\] and SERPINB4 \[[@pone.0151465.ref023]\], respectively) in CNS-PNETs. Like SERPINB9, expression of SERPINB1 and SERPINB4 was acquired in CNS-PNETs. We found SERPINB4 expression in four CNS-PNETs, of which two cases turned out to be also SERPINB1 positive ([Fig 1](#pone.0151465.g001){ref-type="fig"}, [Table 1](#pone.0151465.t001){ref-type="table"}). These data suggest that SERPINB1, SERPINB4, and SERPINB9 are differentially expressed in pediatric CNS-PNETs. Interestingly, besides these serpins, all tumors had high expression of Survivin (caspase-3 inhibitor) and Bcl-2 (cytochrome c release inhibitor), which are both downstream inhibitors of granzyme-induced apoptotic pathways.

The molecular mechanisms and physiological relevance of intracellular serpin expression in pediatric brain tumors remains unknown. SERPINB9, B4, and B1 are known to inhibit granzyme B, M, and H, respectively, and are therefore likely to contribute to evasion of granzyme-induced cytotoxicity \[[@pone.0151465.ref022]--[@pone.0151465.ref024]\]. However, we cannot exclude that these serpins also play other roles in tumorigenesis. Recently, Valiente et al showed that expression of neuroserpin and SERPINB2 are essential for developing brain metastases in patients with lung and breast cancer. Expression of these serpins inhibited plasminogen activator and FAS-L induced cytotoxic cell death by reactive astrocytes and is therefore a marker for poor prognosis \[[@pone.0151465.ref025]\]. Furthermore, SERPINB1 expression in glioma and glioblastoma cell lines seems to be a marker for good prognosis, because it inhibits tumor cell migration and invasion \[[@pone.0151465.ref026]\]. Finally, SERPINB4 expression in patients with squamous cell carcinomas is associated poor prognosis and SERPINB4 can inhibit both radiation- and TNF-induced apoptosis, probably by inhibition of the p38 MAPK pathway and the proteolytic activity of endogenous cathepsin G, respectively \[[@pone.0151465.ref027], [@pone.0151465.ref028]\]. Whether CNS-PNETs with high serpin expression are more prone to be aggressive and more resistant towards (immuno)therapies requires further study,

Conclusion {#sec012}
==========

In conclusion, we have demonstrated that several immune cell subsets can infiltrate pediatric CNS-PNETs, although the activation status of the cytotoxic cells (granzyme B) is variable. Pediatric CNS-PNETs might evade immune recognition by downregulating cell surface MHC-I and CD1d expression. We show that brain tumors can acquire expression of SERPINB1, SERPINB4, and SERPINB9 as a potential mechanism to resist granzyme-induced cytotoxicity. Although the mechanistic insights remain to be elucidated. This study hints to the putative implications of serpin expression for the success rate of immunotherapy in CNS-PNET patients. To predict clinical outcome and response to immunotherapy, further study is required in larger pediatric CNS-PNET cohorts as wells as in the currently running clinical trial of pediatric medulloblastomas/CNS-PNET immunotherapy, in which dendritic cell vaccination and adoptive cellular immunotherapy with cytotoxic lymphocytes is employed \[Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH), University of Florida, NCT01326104\].
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